BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,910,072 | -25.5% | 174,968 | -10.7% | 0.03% | -24.4% |
| Q2 2023 | $15,988,705 | -43.9% | 195,868 | -49.1% | 0.04% | -44.6% |
| Q1 2023 | $28,523,681 | +51.6% | 384,468 | +69.4% | 0.07% | +39.6% |
| Q4 2022 | $18,811,108 | -7.4% | 226,968 | +217.5% | 0.05% | -10.2% |
| Q3 2022 | $20,304,000 | +163.9% | 71,492 | +222.2% | 0.06% | +168.2% |
| Q2 2022 | $7,693,000 | +14.6% | 22,192 | +43.2% | 0.02% | +22.2% |
| Q1 2022 | $6,712,000 | -30.2% | 15,500 | -16.6% | 0.02% | -25.0% |
| Q4 2021 | $9,618,000 | +230.9% | 18,592 | +209.9% | 0.02% | +200.0% |
| Q3 2021 | $2,907,000 | +72.7% | 6,000 | -11.7% | 0.01% | +60.0% |
| Q3 2020 | $1,683,000 | +237.3% | 6,792 | +183.9% | 0.01% | +400.0% |
| Q2 2019 | $499,000 | +23.2% | 2,392 | -12.6% | 0.00% | 0.0% |
| Q2 2018 | $405,000 | -53.2% | 2,736 | -52.3% | 0.00% | -50.0% |
| Q1 2018 | $866,000 | +23.0% | 5,736 | -1.5% | 0.00% | 0.0% |
| Q3 2017 | $704,000 | +10.5% | 5,825 | +0.1% | 0.00% | -33.3% |
| Q3 2016 | $637,000 | +100.9% | 5,817 | +69.3% | 0.00% | 0.0% |
| Q4 2014 | $317,000 | – | 3,436 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |